Lead Product(s) : Azenosertib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Azenosertib Shows Activity in Platinum-Resistant Ovarian Cancer
Details : ZN-c3 (azenosertib), is a potentially first-in-class and best-in-class WEE1 inhibitor being investigated for patients with Cyclin E1+ platinum-resistant ovarian cancer.
Product Name : ZN-c3
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 29, 2025
Lead Product(s) : Azenosertib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Azenosertib,Niraparib Tosylate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zentalis Announces Fast Track Designation for Azenosertib and Upcoming Data Event
Details : ZN-c3 (azenosertib), is a potentially first-in-class and best-in-class WEE1 inhibitor being investigated for advanced solid tumors and hematologic malignancies.
Product Name : ZN-c3
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 09, 2025
Lead Product(s) : Azenosertib,Niraparib Tosylate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Azenosertib,Niraparib Tosylate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zentalis Pharmaceuticals Reports FDA Lifts Partial Clinical Hold on Azenosertib Studies
Details : ZN-c3 (azenosertib), is a potentially first-in-class and best-in-class WEE1 inhibitor being investigated for advanced solid tumors and hematologic malignancies.
Product Name : ZN-c3
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 16, 2024
Lead Product(s) : Azenosertib,Niraparib Tosylate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Azenosertib,Niraparib Tosylate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program
Details : ZN-c3 (azenosertib), is a potentially first-in-class and best-in-class WEE1 inhibitor being investigated for advanced solid tumors and hematologic malignancies.
Product Name : ZN-c3
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 18, 2024
Lead Product(s) : Azenosertib,Niraparib Tosylate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Azenosertib,Niraparib Tosylate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ZN-c3 (azenosertib) is a potentially first-in-class and best-in-class small molecule WEE1 inhibitor in development for the treatment of ovarian cancer and uterine serous carcinoma.
Product Name : ZN-c3
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 06, 2023
Lead Product(s) : Azenosertib,Niraparib Tosylate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Azenosertib,Niraparib Tosylate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zentalis Pharmaceuticals Announces Overview of Clinical and Preclinical Data Presented at AACR
Details : ZN-c3 showed robust clinical activity in an advanced, sicker patient population (57% had prior pembrolizumab/lenvatinib use), specifically demonstrating a deepening of tumor response, which included one patient who achieved an unconfirmed complete respon...
Product Name : ZN-c3
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 04, 2022
Lead Product(s) : Azenosertib,Niraparib Tosylate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Azenosertib,Cetuximab
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Zentalis Pharmaceuticals Announces First ZN-c3 Clinical Development Collaboration with Pfizer
Details : Zentalis and Pfizer will initiate a Phase 1/2 dose escalation study of ZN-c3 in combination with encorafenib and cetuximab—an FDA-approved standard of care known as the BEACON regimen—in patients with BRAF V600E-mutated metastatic colorectal cancer (...
Product Name : ZN-c3
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 24, 2022
Lead Product(s) : Azenosertib,Cetuximab
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Azenosertib,Niraparib Tosylate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ZN-c3 in combination with chemotherapy demonstrated strong anti-tumor activity in a heavily pretreated population, with an ORR of 30.2% across all chemotherapy cohorts, also exhibit a better hematologic and gastrointestinal tolerability profile within We...
Product Name : ZN-c3
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 04, 2022
Lead Product(s) : Azenosertib,Niraparib Tosylate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Azenosertib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ZN-c3, a potent and selective WEE-1 inhibitor demonstrates durable clinical activity and good tolerability in varying indications anti-tumor activities in combination with other targeted therapies and overcomes PARP inhibitor resistance.
Product Name : ZN-c3
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 03, 2022
Lead Product(s) : Azenosertib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Azenosertib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Pfizer Inc
Deal Size : $25.0 million
Deal Type : Financing
Zentalis Pharmaceuticals Announces $25 Million Equity Investment from Pfizer
Details : Zentalis intends to use the net proceeds of the offering to help fund ongoing and planned clinical trials, including studies of ZN-c3, its Wee1 inhibitor, and ZN-d5, its BCL-2 inhibitor, and for working capital and general corporate purposes.
Product Name : ZN-c3
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 27, 2022
Lead Product(s) : Azenosertib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Pfizer Inc
Deal Size : $25.0 million
Deal Type : Financing